- 1 Role of β -lactamases and efflux pumps in multidrug resistance in *Pseudomonas*
- 2 aeruginosa isolated from patients in the Intensive Care Unit in the northeast of
- 3 Brazil

11 12

13

14 15

16

17 18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

- 4 Marília S. Maia ^{1, 2}#, Lavouisier F.B. Nogueira ^{1, 2}#, Marco A.F Clementino ^{1, 2}#, Jose
- 5 Q.S. Filho ^{1, 3}, Ila F.N. Lima ⁴, José K. Sousa ¹, Deiziane V.S. Costa ¹, Jorge L.N.
- 6 Rodrigues ⁴, Luciana V.C. Fragoso ⁴, Alexandre Havt ^{1, 2}, and Aldo A.M. Lima ^{1, 2, 3, *}
 - ¹ Institute of Biomedicine, School of Medicine, Federal University of Ceara, Fortaleza-Ceara 60430-270, Brazil.
 - Postgraduate Medical Microbiology Program, Department of Medicine, Federal University of Ceara, Fortaleza-Ceara 60430-270, Brazil.
 - Postgraduate Medical Sciences Program, Department of Medicine, Federal University of Ceara, Fortaleza-Ceara 60430-270, Brazil.
 - Hospital Universitário Walter Cantídio, Federal University of Ceara, Fortaleza-Ceara 60430-270, Brazil.
 - * Correspondence: alima@ufc.br
 - # autores contribuíram igualmente para este trabalho
 - e-Mails: mmaia800@gmail.com, lavouisier@gmail.com, mclementino@ufc.br, jquirinof@gmail.com, jlal.lima@ebserh.gov.br, jorge1207@gmail.com, lal.lima@ufc.br, alavt@ufc.br, <a href="mail.com"

Abstract

Pseudomonas aeruginosa is an opportunistic pathogen of great clinical relevance in intensive care units (ICU), mainly due to its high resistance to various antimicrobials, which sometimes makes effective treatment impossible, leading to high morbidity and mortality in patients in critical situations. In this study, we aimed to detect variants of genes encoding β-lactamases and efflux pumps in P. aeruginosa isolates resistant to βlactams, fluoroquinolones and aminoglycosides. All genes belonging to the subfamilies were included in the study: bla_{SHV}, bla_{TEM}, bla_{NDM}, bla_{KPC}, bla_{GES}, bla_{CTX-M}. In addition, we investigate the most relevant variants of the bla_{OXA} subfamily and genes belonging to the efflux pumps of the Mex family. We tested 54 isolates of P. aeruginosa, finding a high prevalence of phenotypic resistance to the antimicrobials piperacillin with tazobactam, ceftazidime, cefepime, imipenem and meropenem, with a high positivity in the presence of resistance genes related to carbapenems and spectrum β-lactamases extended, mainly for the bla_{KPC} genes with 81.49%, followed by bla_{CTXM-2} with 72.22% and bla_{CTXM-1} with 66.66%. In relation to the presence of Mex family efflux pumps there was a rate of 100% of positivity. These results suggest that the P. aeruginosa strains isolated have an arsenal of genes encoding β-lactamases capable of inducing phenotypic patterns of resistance to several antimicrobials commonly used for these infections, making treatment difficult for the patients in this clinical ward.

Key words: *P. aeruginosa*; Antimicrobial Resistance; β -lactamases genes; efflx pumps genes; Intensive Care Unit.

Introduction

Antimicrobial-resistant Gram-negative bacteria (GNB) are of particular concern worldwide due to their high morbidity and mortality, particularly in intensive care units (ICUs) [1]. The emergence and spread of microbial resistance is a global problem that has profound consequences for public health and the economy [2].

Due to the selective pressure exerted by the frequent use of antimicrobials and the long stay of patients with compromised immune systems, infections related to multidrug-resistant (MDR) microorganisms are prevalent in ICU facilities [3,4]. Healthcare-associated infections (HAIs) caused by MDR are considered a threat to public health, as they limit or even make available therapeutic options unfeasible, which increases the severity and, consequently, the morbidity and mortality rates of those affected, increasing patient length of stay and hospital costs [1].

In this scenario, *Pseudomonas aeruginosa*, an important opportunistic Gramnegative pathogen that causes a variety of infectious diseases, has acquired resistance to several antimicrobials in recent times [5,6]. According to the latest antimicrobial resistance surveillance report from the European Center for Disease Prevention and Control (ECDC), who evaluated *P. aeruginosa* isolates from 2013 to 2016, the average of *P. aeruginosa* isolates with combined resistance (resistance to three or more antimicrobial groups, including carbapenems) was 12.9% [7]. Furthermore, a study carried out in Singapore observed a percentage of 11.5% of health-related infections caused by *P. aeruginosa*, in which 23% of these isolates were resistant to carbapenems [8]. *P. aeruginosa* is included in the "critical" category of the World Health Organization (WHO) priority list of bacterial pathogens for which research and development of new antimicrobials are urgently needed [1].

The main mechanisms involved in antimicrobial resistance in *P. aeruginosa* strains are enzymatic mechanisms, where β -lactamases stand out, and efflux pumps. [5,9]. *P. aeruginosa* isolates contain a variety of β -lactamases, such as the carbapenemases KPC, GES, IMP, VIM, NDM and SPM, and are distributed throughout the world [10,11,12].

Efflux pumps are related to resistance to several antimicrobials, particularly those belonging to the AcrAB-TolC and Mex pump families belonging to the nodulation-division resistance superfamily (RND). Efflux pumps not only mediate intrinsic and acquired microbial resistance, but are also involved in other functions, including bacterial stress response and pathogenicity [13,14,15].

Based on this, we sought to detect variants of genes encoding β -lactamases and efflux pumps, belonging to the RND superfamily, in *P. aeruginosa* isolates resistant to β -lactams, fluoroquinolones and aminoglycosides isolated from patients admitted to an intensive care ward a tertiary care health unit in the city of Fortaleza-CE, with the purpose of tracing the resistance profile of the strains isolated in the health unit in question.

Material and methods

Obtaining bacterial isolates and identification

For the following study, 259 samples were collected from patients admitted to the clinical ICU of a tertiary care health unit in the city of Fortaleza-CE, who presented an infectious condition (defined by the attending ward physicians) involving different anatomical sites. Those microorganisms that were identified as Gram-negative bacteria, resistant to one or more groups of antimicrobials were included: β -lactams, fluoroquinolones, aminoglycosides, macrolides, and glycopeptides. These samples were made available for the study through approval from the research ethics committee of the health unit in question (n° 3.276.113).

With the aim of diagnosing potential etiological agents, blood culture samples and other noble liquids were inoculated in specific bottles and incubated in the equipment BacT/Alert® 3D (BioMérieux, Marcy l'Etoile, France). The other biological materials were sown in specific culture media using a qualitative or quantitative sowing technique, in order to obtain isolated colonies. Plates were incubated at 37±2°C for 18-24 hours.

The bacterial isolates were identified and tested for their susceptibility to antimicrobials using the automated method VITEK® 2 Compact (BioMérieux, Marcy l'Etoile, France), according to the manufacturer's recommendations. Minimum inhibitory concentrations were interpreted according to the Clinical and Laboratory Standards Institute [16] and with the Brazilian committee on antimicrobial susceptibility testing [17,18]. For quality control of sensitivity tests, strains from the American Type

Culture Collection (ATCC) were used. Specimens that had a resistance profile that fit the research objectives were included in the study.

Selection of analyzed strains

A total of 258 isolates were analyzed, among which those identified as P. aeruginosa were included in this study. Strains of P. aeruginosa resistant to one or more groups of β -lactam antimicrobials, fluoroquinolones and aminoglycosides were then used to investigate their genetic resistance profile. MDR was defined as multidrug resistant to ≥ 1 agent in ≥ 3 classes of antimicrobials and extending drug resistance (XDR) as drug susceptibility to ≤ 2 classes of antimicrobials agents.

Extraction of bacterial DNA

The isolates maintained in trypticase soy broth were incubated overnight in a bacteriological oven at 37°C, at 200 rpm, for subsequent extraction of bacterial DNA. To extract genetic material, the Wizard Genomic DNA Purification extraction and purification kit was used (Promega, Madison, USA), according to the manufacturer's recommendations.

After extraction, all samples were quantified by spectrophotometry using the NanoDropTM 2000 (Thermo Fisher Scientific, Waltham, Massachusetts, USA) and stored in a -80°C freezer until used in the experiments.

Detection of resistance-related genes by molecular biology

The selected strains of *P. aeruginosa* were analyzed by real-time PCR (qPCR) using QuantStudio 3® (Applied Biosystems, Massachusetts, USA), using specific primers, for the detection of 13 genes encoding efflux pumps (**Table 1**) and 14 genes encoding β -lactamases described by Nogueira and collaborators [19]. Reactions were standardized using positive controls and negative controls (milliQ water) to determine the most efficient qPCR conditions.

Table 1 Description of genes related to encoding efflux pumps.

Efflux pumps	Gene	Function	Primers	Primer sequence (5'-3')	Product size (bp)	At (°C)
MexAB-OprM	mexA	membrane fusion	MexA F	GACAAGTGGCTGGTTACCGA	96	63
		protein	MexA R	CACGGTCTTCACCTCGACAC		
	mexB	Inner membrane	MexB F	GTCGATTCCGTTCTCGGTGA	158	65

				•		
		transporter	MexB R	ACTCCACGATGAGAATGGCG		
		membrane fusion	MexC F	CGTGCAATAGGAAGGATCGG	104	CO
MCD OI	mexC	protein	MexC R	TCCACCGGCAACACCATTT	104	60
MexCD-OprJ	mexD	Inner membrane	MexD F	TACACCCTGATCCCGTCCAT	170	64
	mexD	transporter	MexD R	ATGATCCGCTCGACGTTCTC	170	04
	mexE	membrane fusion	MexE F	CTGAGCTTCACCCGGATCAC	140	61
Manee On a	mexE	protein	MexE R	GCGTCGAAGTAGGCGTAGAC	140	64
MexEF-OprN	mexF	Inner membrane	MexF F	TCATCAAGGTCAGCGACACC	169	64
		transporter	MexF R	CACTCGTAGGTCATGCCGTT	109	
	mexG		MexG F	TGCAGCGCTTCATCGATAACT	120	64
MayCIII OnmD	mexG	membrane protein	MexG R	GGCTGGCCTGATAGTCGAAC	120	04
MexGHI-OpmD	mexH	membrane fusion	MexH F	TCATCAAGGTCAGCGACACC	124	65
		protein	MexH R	CACTCGTAGGTCATGCCGTT	124	
	mexV	membrane fusion	MexV F	TACTGTTCCTTTCCGGCGAC	170	61
MayVW OnuM	mex v	protein	MexV R	TTCGCTTTTCGAGATGGCCT	170	
MexVW-OprM		mambrana protain	MexW F	CCTCGGTCTACATCGGCATC	181	65
	IIIex vv	membrane protein	MexW R	CCGAGGGTCTTCACCACTTC	161	03
MexXY-OprM	mexX	mambrana protain	MexX F	TGCTGTTCCAGATCGACCCT	127 6	
	mexX m	membrane protein	MexX R	TCCTTGATCAGGTCGGCGTA	127	60
	mexY	membrane fusion	MexY F	GTCAACCAAATGACCGCCAC	134	65
	illex i	protein	MexY R	ATGTTGTAGCTCACGCCCTC	154	03

At= Annealing temperature

Data Analysis

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

Fisher's test was used to compare the proportion of occurrence of a variable between groups. The confidence interval was 95% and the test was considered statistically significant when P < 0.05, using the IBM Statistical Package for the Social Sciences Version 21 program (SPSS Statistics Software, Nova York, EUA).

Results

Prevalence of *P. aeruginosa* in the study

During the period of this study, 258 Gram-negative bacteria were isolated, of which 20.9% (54/258) were identified as *P. aeruginosa*, which were isolated from different anatomical sites of hospitalized patients. The tracheal aspirate was the sample that obtained the highest number of *P. aeruginosa* isolates with 74.1% (40/54), followed by blood samples with 11.11% (6/54), bronchoalveolar lavage 7.40 % (4/54), of abdomen 1.85% (1/54), of tissue fragment 1.85% (1/54), of sacral eschar 1.85% (1/54) and of tendon 1, 85% (1/54).

Antimicrobial resistance phenotype tested in *P. aeruginosa* isolates

Fifteen antimicrobials from different classes were tested, in which P. aeruginosa isolates obtained a resistance rate of 100% to cefoxitin (32/32),

Bp= Base pairs; Primer F = Forward; Primer R = Reverse

ceftriaxone (25/25), cefuroxime axetil (32/32) and tigecycline (32/32), thus confirming the intrinsic resistance of the pathogen to these antimicrobials. The combination of piperacillin with tazobactam obtained a rate of 74.4% (32/43), followed by ceftazidime and cefepime both with the same percentage of 63.4% (33/52), imipenem with 61.2% (30/49), meropenem with 56.2% (27/48), ciprofloxacin 54.9% (28/51), gentamicin 41.5% (22/53) and, finally, amikacin with 28.3% (15/53), as shown in **Figure 1**. All tested isolates did not demonstrate a phenotype of resistance to colistin, ceftazidime / avibactam and ceftolozone/tazobactam.

Figure 1. Prevalence of *P. aeruginosa* isolates resistant to β-lactam antimicrobials (A) and aminoglycosides, quinolones and glycylcycline (B) evaluated, demonstrating a phenotypic profile of resistance to multiple antimicrobials in more than 50% of the isolates, with the exception of colistin, ceftazidime/ avibactam, ceftolozone/ tazobactam, gentamicin and amikacin.

The tested isolates of *P. aeruginosa* obtained a percentage of 61.11% (33/54) for MDR microorganisms, followed by a percentage of 55.5% (30/54) for XDR microorganisms and a percentage of 46.2% (25/54) for carbapenem-resistant microorganisms.

Detection of resistance genes in *P. aeruginosa* isolates by qPCR

For the detection of genes encoding β-lactamases, the highest percentage found was the bla_{KPC} gene with 81.49% (44/54), followed by bla_{CTXM-2} with 72.22% (39/54), bla_{CTXM-1} with 66.66% (36/54), bla_{CTXM-5} with 59.25% (32/54), bla_{SHV} with 40.74% (22/54), bla_{TEM} and $bla_{OXA-23-like}$ with 38.89% (21/54), bla_{NDM} with 29.6% (16/54), bla_{GES} and $bla_{OXA-51-like}$ with 24% (13/54), $bla_{OXA-24/40-like}$ with 20.4% (11/54), bla_{CTXM-3} with 11.11% (6/54), bla_{CTXM-4} with 9.26% (5/54) and there was no detection of the bla_{OXA-48-like} gene in the isolates, as shown in **Figure 2**, grouped according to the Ambler classification.

Figure 2. Prevalence of β-lactam resistance genes among P. aeruginosa isolates, grouped according to the Ambler classification, (A) in which there is a high detection

rate for class A ESBL ($bla_{\text{CTX-M}}$ do clade 2, 1 and 5 respectively; bla_{SHV} ; bla_{TEM}), (B) marked presence of the bla_{KPC} carbapenemase, (C) in addition to the identification of $bla_{\text{OXA-23-like}}$, $bla_{\text{OXA-51-like}}$ and $bla_{\text{OXA-24/40-like}}$ commonly associated with *Acinetobacter baumannii* strains.

Association of the presence of resistance genes with the resistance phenotype

The association between the prevalence of the 14 genes encoding β -lactamases and the β -lactam resistance phenotype identified in *P. aeruginosa* isolates was evaluated. The distribution of the percentage of genes detected in the isolates tested for the antimicrobials cefepime and ceftazidime showed a higher positivity rate for the genes bla_{KPC} , bla_{CTXM-2} , bla_{CTXM-1} , bla_{CTXM-5} , bla_{SHV} with 82.7% (43/52), 75% (39/52), 69.2% (36/52), 61.5% (32/52) and 42.3% (22/52), respectively. The presence of the bla_{TEM} and $bla_{OXA-23-like}$ genes were associated with phenotypic resistance to the antimicrobials cefepime and ceftazidime (P= 0.017; OR 5.66; 95% CI 1.38-23.21) and (P=0.041; OR 3.98; 95% CI 1.08 – 14.58), respectively, as shown in **Table 2**.

Table 2 Percentage of positivity of genes encoding β -lactamases in *P. aeruginosa* isolates in the groups resistant and susceptible to the antimicrobials cefepime and ceftazidime.

Coding genes β-lactamases	Total N=52(%)	Resistant N=33(%)	Susceptible N=19(%)	P valor	OR	95% CI
bla_{KPC}	43 (82.7)	27 (81.8)	16 (84.2)	1.0000	0.84	0.18 - 3.85
$bla_{ ext{CTXM-2}}$	39 (75)	25 (75.8)	14 (73.7)	1.0000	1.11	0.30 - 4.07
$bla_{ ext{CTXM-1}}$	36 (69.2)	24 (72.7)	12 (63.2)	0.5405	1.55	0.46 - 5.20
$bla_{ ext{CTXM-5}}$	32 (61.5)	19 (57.6)	13 (68.4)	0.5579	0.62	0.19 - 2.05
$bla_{ m SHV}$	22 (42.3)	13 (39.4)	9 (47.37)	0.3969	0.58	0.18 - 1.82
$bla_{ m OXA-23-like}$	21 (40.4)	17 (51.5)	4 (21)	0.041*	3.98	1.08 - 14.58
bla_{TEM}	20 (38.5)	17 (51.5)	3 (15.8)	0.017*	5.66	1.38-23.21
$bla_{ m NDM}$	16 (30.7)	10 (30.3)	6 (31.6)	1.0000	0.94	0.27 - 3.19
$bla_{ ext{GES}}$	13 (25)	8 (24.2)	5 (26.3)	1.0000	0.89	0.24 - 3.27
$bla_{ m OXA-51-like}$	13 (25)	11 (33.3)	2 (10.5)	0.0987	4.25	0.82 - 21.79
$bla_{ m OXA-24/40-like}$	10 (19.2)	8 (24.2)	2 (10.5)	0.2925	2.72	0.51 - 14.42
$bla_{ ext{CTXM-3}}$	6 (11.5)	3 (9)	3 (15.8)	0.6563	0.53	0.09 - 2.95

bla _{CTXM-4}	5 (9.3)	4 (12.1)	1 (5.3)	0.6410	2.48	0.25 - 24.02
$bla_{ m OXA ext{-}48 ext{-}like}$	0	0	0	0	0	0

OR= Odds ratio; CI= Confidence interval.

The most frequently identified genes in the isolates tested for the antimicrobial piperacillin in combination with the β -lactamase inhibitor tazobactam were bla_{KPC} , bla_{CTXM-2} , bla_{CTXM-5} , bla_{SHV} and $bla_{OXA-23-like}$ with percentages of 81.4% (35/43), 74.4% (32/43), 67.4% (29/43), 65.1% (28/43), 41.8% (18/43) and 41.8% (18/43), respectively. There was no statistical significance between the genes studied and the phenotype.

The percentage of positivity of the genes encoding β -lactamases detected in the isolates tested for the antimicrobial imipenem indicated a higher positivity rate for the genes bla_{KPC} , bla_{CTXM-2} , bla_{CTXM-1} , bla_{CTXM-5} and bla_{SHV} with percentages of 79.6% (39/49), 71.4% (35/49), 67.3% (33/49), 57.1% (28/49) and 38.7% (19/49), respectively. The presence of the bla_{TEM} gene achieved statistical significance with phenotypic resistance to the antimicrobial imipenem (P=0.018; OR 5.33; 95% CI 1.28-22.20), as shown in **Table 3**.

Table 3 Percentage of positivity of genes encoding β -lactamases in *P. aeruginosa* isolates in the resistant and susceptible groups to the antimicrobial imipenem.

Coding genes β-lactamases	Total N=49(%)	Resistant N=30(%)	Susceptible N=19(%)	P valor	OR	95% CI
bla_{KPC}	39 (79.6)	24 (80)	15 (78.9)	1.0000	1.06	0.25 - 4.41
$bla_{ ext{CTXM-2}}$	35 (71.4)	20 (66.6)	15 (78.9)	0.5185	0.53	0.13 - 2.03
$bla_{ ext{CTXM-1}}$	33 (67.3)	19 (63.3)	14 (73.7)	0.5412	0.61	0.17 - 2.18
$bla_{ ext{CTXM-5}}$	28 (57.1)	15 (50)	13 (68.4)	0.2467	0.46	0.13 - 1.53
$bla_{ m SHV}$	19 (38.7)	10 (33.3)	9 (47.3)	0.3774	0.55	0.17 - 1.80
$bla_{ m OXA-23-like}$	18 (36.7)	13 (43.3)	5 (26.3)	0.3621	2.14	0.61 - 7.48
bla_{TEM}	18 (36.7)	15 (50)	3 (15.7)	0.018*	5.33	1.28 - 22.20
$bla_{ m NDM}$	15 (30.6)	7 (23.3)	8 (42.1)	1.0000	0.87	0.27 - 2.81
$bla_{ m OXA ext{-}51 ext{-}like}$	12 (24.5)	10 (33.3)	2 (10.5)	0.0948	4.25	0.81 - 22.14
$bla_{ ext{GES}}$	12 (24.5)	6 (20)	6 (31.6)	0.4975	0.54	0.14 - 2.02
$bla_{ m OXA-24/40-like}$	8 (16.3)	6 (20)	2 (10.5)	0.4583	2.12	0.38 - 11.83

bla _{CTXM-3}	5 (10.2)	3 (10)	2 (10.5)	1.0000	0.94	0.14 - 6.25
$bla_{ ext{CTXM-4}}$	3 (6.1)	3 (10)	0	0.2730	4.96	0.24 – 101.7
$bla_{ m OXA-48-like}$	0	0	0	0	0	0

OR= *Odds ratio*; CI= Confidence interval.

The distribution of the percentage of positivity of the genes encoding β -lactamases detected in the isolates tested for the antimicrobial meropenem showed a higher rate for the genes bla_{KPC} , bla_{CTXM-2} , bla_{CTXM-1} , bla_{CTXM-5} and bla_{SHV} with percentages of 79.6% (39/49), 71.4% (35/49), 67.3% (33/49), 57.1% (28/49) and 38.7% (19/49), respectively. The presence of bla_{TEM} and $bla_{OXA-51-like}$ genes achieved statistical significance with phenotypic resistance to the antimicrobial meropenem (P= 0.034; OR 4.57; 95% CI 1.21-17.23) and (P=0.043; OR 5.58; 95% CI 1.06 – 29.20), respectively, as shown in **Table 4**.

Table 4 Percentage of positivity of genes encoding β -lactamases in *P. aeruginosa* isolates in the resistant and susceptible groups to the antimicrobial meropenem.

Coding genes β-lactamases	Total N=48(%)	Resistant N=27(%)	Susceptible N=21(%)	P valor	OR	95% CI
bla_{KPC}	38 (79.1)	21 (77.7)	17 (80.9)	1.0000	0.82	0.19 - 3.40
$bla_{ ext{CTXM-2}}$	35 (72.9)	18 (66.6)	17 (80.9)	0.3377	0.47	0.12 - 1.81
$bla_{ ext{CTXM-1}}$	35 (72.9)	19 (70.3)	16 (76.2)	0.7502	0.74	0.20 - 2.72
$bla_{ ext{CTXM-5}}$	28 (58.3)	13 (48.1)	15 (71.4)	0.1437	0.37	0.11 - 1.24
$bla_{ m SHV}$	21 (43.7)	10 (37)	11 (52.4)	0.3820	0.53	0.16 - 1.70
$bla_{ m OXA-23-like}$	19 (39.5)	13 (48.1)	6 (28.6)	0.2369	2.32	0.69 - 7.79
bla_{TEM}	18 (37.5)	14 (51.8)	4 (19)	0.034*	4.57	1.21 – 17.23
$bla_{ m NDM}$	16 (33.3)	7 (25.9)	9 (42.8)	0.2373	0.46	0.13 - 1.58
$bla_{ m OXA-51-like}$	12 (25)	10 (37)	2 (9.5)	0.043*	5.58	1.06 - 29.20
$bla_{ ext{GES}}$	13 (27)	6 (22.2)	7 (33.3)	0.5161	0.57	0.15 - 2.06
$bla_{ m OXA-24/40-like}$	8 (16.6)	6 (22.2)	2 (9.5)	0.4371	2.71	0.48 - 15.11
$bla_{ ext{CTXM-3}}$	6 (12.5)	3 (11.1)	3 (14.3)	1.0000	0.75	0.13 - 4.16
$bla_{ ext{CTXM-4}}$	2 (4.2)	2 (7.4)	0	0.4973	4.21	0.19 - 92.73
$bla_{ m OXA ext{-}48 ext{-like}}$	0	0	0	0	0	0

The genes that encode the efflux pumps of the MEX family were evaluated by operon, in which the distribution of the percentage of positivity found in the tested isolates was 100% for the genes MEX-AB, MEX-EF, MEX-GH, MEX-VW, MEX-XY and followed by a percentage of 96.3% for the MEX-CD gene. No statistical tests were performed regarding efflux pumps due to the high positivity of the genes.

Discussion

P. aeruginosa is an opportunistic pathogen with considerable clinical importance in intensive care units, mainly due to its high resistance to several antimicrobials, making effective treatment impossible, leading to high morbidity and mortality in these patients in critical situations [20].

This study found a prevalence of 20.9% of colonization by this microorganism, among Gram-negative isolates resistant to at least one antimicrobial, which represents a similar percentage with other studies, as demonstrated in a report issued by ANVISA [21], where *P. aeruginosa* was the third most isolated microorganism among Gramnegative bacteria reported in bloodstream infections, with a percentage of 16.2%. In the United States, Sader and collaborators, analyzing samples of Gram-negative bacteria isolated from ICU and non-ICU patients, collected in 70 hospital centers, from 2018 to 2020, found a prevalence of 23.5% of *P. aeruginosa* isolated in patients admitted to ICU [22]. Dunphy and collaborators carried out a study in outpatient and hospital environments in regions of Virginia, United States, over a period of one year (2019-2020), collecting several samples, in which they identified a prevalence of 60% of *P. aeruginosa* isolates from different anatomical sites, analyzing 971 isolates collected from 590 patients [23], in which these studies demonstrate a variability in the detection rate of this pathogen.

In this study, the largest number of *P. aeruginosa* isolates was obtained through bronchial lavage secretions with a percentage of 74.1%, similar results were reported in other studies in which *P. aeruginosa* was the most isolated pathogen in lung secretions (bronchial lavage and tracheal aspirate) [23,24]. Respiratory infections caused by this pathogen are quite common, especially in hospital environments, and may be related to the handling of invasive procedures on patients, such as tracheal intubation, aspirations and the need for mechanical pulmonary ventilation [11,20].

In order to identify the phenotypic profile of antimicrobial resistance of P. aeruginosa strains isolated in the hospital environment, antimicrobials from different

classes were tested, in which the highest resistance rate of *P. aeruginosa* isolates was 100% for cephalosporins of second and third generation cefoxitin, ceftriaxone and cefuroxime axetil. Several studies corroborate this result demonstrating that the only third generation cephalosporin with action on strains of *P. aeruginosa* is ceftazidime [25,26].

In agreement with the findings of this study, research carried out in the United States by Sader and collaborators [22] on *P. aeruginosa* strains collected over a two-year period and a study carried out in Rio de Janeiro over a 20-year period [27], found similar results for the antimicrobials piperacillin with tazobactam, ceftazidime, cefepime and meropenem in strains of *P. aeruginosa*. These studies indicated a growing increase in the rate of resistance to antimicrobials over the years.

Regarding third-generation cephalosporins in combination with β -lactamases inhibitors (ceftazidime with avibactam and ceftolozone with tazobactam), in our study there was no detection of the resistance phenotype. This result is in line with what was expected since ceftolozone with tazobactam is an antipseudomonal antimicrobial that acts on multidrug-resistant strains of *P. aeruginosa* [28,29]. The antimicrobial ceftazidime with avibactam acts on multidrug-resistant *P. aeruginosa* strains that are ESBL, AmpC and KPC positive, as this inhibitor removes the serine residue that is the active portion of the enzyme, however, these antimicrobials do not act on metallo β -lactamases positive strains [30], indicating the action of β -lactamases inhibitors in light of the high positivity of the presence of genes encoding KPC in our study.

The susceptibility rates obtained in our study are in agreement with studies that have reported good activity of ceftazidime associated with avibactam and ceftolozone associated with tazobactam. López-Calleja and collaborators [31] carried out a study in a university hospital located in Spain, in which they analyzed the susceptibility profile of 12 MDR strains of *P. aeruginosa* and 117 XDR strains of *P. aeruginosa* against ceftolozone associated with tazobactam, and detected a susceptibility rate of 92.2% in these isolates. In the same context, research carried out by the Global Antimicrobial Testing Leadership and Surveillance Program, collected 2.521 clinical isolates of *P. aeruginosa* from 41 medical centers in 10 countries in Latin America, from 2017 to 2019, in which they found a rate of 86.9% of isolates susceptible to ceftazidime associated with avibactam [32]. Therefore, these studies corroborate our results, showing that third-generation cephalosporins in combination with β-lactamases inhibitors are a good therapeutic option.

In order to identify the presence and prevalence of genes encoding β -lactamases in the university hospital, we analyzed 14 genes, where the most prevalent gene was bla_{KPC} with 81.49% positivity in the isolates. In a study carried out by Hu and collaborators [33], researching strains of carbapenem-resistant P. aeruginosa isolated from the intestine, from 2014 to 2019, the presence of the bla_{KPC-2} gene was identified in 21.1% of the isolates. Likewise, a prospective and observational cohort study, carried out from 2018 to 2019, analyzed 972 patients admitted with confirmed infection by carbapenem-resistant P. aeruginosa in 44 hospitals, distributed across three continents, identifying the presence of the bla_{KPC-2} gene in 49% of isolates, demonstrating the circulation of this gene that confers resistance to carbapenems in various parts of the world [34]. Carbapenems have the widest spectrum of action for the treatment of infections caused by multidrug-resistant bacteria, which is why the emergence and spread of carbapenemases has become a major public health problem. Our study detected a rate well above the studies cited, as we used a bla_{KPC} primer that detects 19 variants, expanding the detection of this β-lactamase, in contrast to just one variant that the studies above investigated.

To understand the association of the β-lactam resistance phenotype with genes related to β-lactamases, we correlated the phenotype and genotype and found a statistical association between resistance to ceftazidime and cefepime with the presence of the bla_{TEM} and $bla_{OXA-23-like}$ genes. This can be explained by the fact that the bla_{TEM} gene has several variants that are ESBLs, capable of hydrolyzing third and fourth generation cephalosporins [35]. In this case, our study used primers that have the ability to detect 167 variants of the bla_{TEM} gene, of which many of these variants are ESBLs. Regarding the $bla_{OXA-23-like}$ gene, which encodes an enzyme capable of hydrolyzing all cephalosporins and carbapenems [36,37], was the first class D carbapenemase to be discovered in a strain of *Acinetobacter baumannii*, in 1985, coincidentally the same year that imipenem was approved for clinical use [38]. Genes belonging to the $bla_{OXA-23-like}$ group can be transmitted by plasmids between species, in which studies have detected the role of plasmids and transposons in the dissemination of the $bla_{OXA-23-gene}$, which has been found in *Acinetobacter* spp., P. aeruginosa, as well as species belonging to the Enterobacteriaceae [36,39,40,41].

The presence of the bla_{TEM} gene was also associated with resistance to carbapenems, imipenem and meropenem; there is no previous information in the literature that corroborates this result in P. aeruginosa. However, a study carried out by

Han and colleagues [42], analyzing strains of *A. baumannii* resistant to carbapenems in a university hospital in China, found an association between the presence of the bla_{TEM} and $bla_{\text{OXA-23-like}}$ genes with the carbapenem resistance phenotype. In research carried out in an Iranian hospital, from 2015 to 2017, resistant strains of *P.aeruginosa* were isolated from patients with nosocomal and non-nosocomial infections and the presence of the $bla_{\text{OXA-23-like}}$ gene was identified in 11.19% of the isolates [43], evidencing the circulation of the OXA group gene in species other than *Acinetobacter*.

Finally, the presence of the $bla_{OXA-51-like}$ gene was associated with resistance to meropenem. $bla_{OXA-51-like}$ encodes a carbapenemase belonging to Ambler class D, which are enzymes intrinsic to *A. baumannii* and are found naturally in the chromosome of this species [36], however, in 2009, Lee and colleagues reported the presence of the bla_{OXA-51} gene in a non-*Acinetobacter* species, in which they identified this gene with an ISAba1 insertion, which was plasmid-encoded and the surrounding sequences suggested that its origin was from *A. baumannii*. In this study, the enzyme encoded by bla_{OXA-51} had the capacity to increase the minimum inhibitory concentration (MIC) of meropenem by up to 256 times, thus conferring resistance to it [44]. However, there is only one study in the literature that reports the presence of the bla_{OXA-51} gene in *P. aeruginosa* strains, which were isolated from outpatients in Maranhão, Brazil [45]. These studies demonstrate the spread of the bla_{OXA-51} gene beyond strains of *A. baumannii*, where this gene was considered a marker for these species.

Regarding the presence of Mex family efflux pumps in *P. aeruginosa* isolates, our study showed a positivity of 96.3% for the gene that encodes the MexCD pump and a positivity of 100% for the rest of the Mex pumps tested. There was no statistical association of efflux pumps in relation to the resistance phenotype due to the high positivity in the isolates, but studies have shown that efflux pumps in *P. aeruginosa* are among one of the main resistance mechanisms that lead to the emergence of MDR strains and XDR. This primary resistance mechanism is responsible for reducing the intracellular concentration of the drug to a subinhibitory concentration at which other resistance mechanisms for specific classes can evolve and be selected, increasing antimicrobial resistance [46,47].

The present study had some limitations, such as: susceptible strains of *P. aeruginosa* were not included in the study for a more detailed epidemiological analysis, no research was carried out into the existence of clones of *P. aeruginosa* circulating in the ICU, no sequencing was carried out positive controls for a more precise validation

of all variants that our method aims to detect and the isolates were not tested for all antimicrobials in a homogeneous way due to clinical implications and procedures adopted by the hospital analyzed in the study. However, our work innovated in the use of primers that could detect a greater number of genes encoding β -lactamases, thus expanding their diagnosis.

The *P. aeruginosa* strains isolated in this study showed a high rate of phenotypic resistance to several antimicrobials, in which these strains have a repertoire of genes encoding β -lactamases capable of inducing these phenotypic patterns of resistance to antimicrobials commonly used for these infections, making treatment difficult or even impossible for the patient.

Author Contributions:

364

365

366

367

368

369

370

371

372

373

374

- 375 Bibliographic review and data collection, Marília S. Maia, Lavouisier F.B. Nogueira,
- 376 Marco A.F Clementino and Aldo A.M. Lima; Methodology, Lavouisier F.B. Nogueira,
- Marília S. Maia, Marco A.F Clementino, Alexandre Havt, Ila F.N. Lima, Jorge L.N.
- 378 Rodrigues, Luciana V. C. Fragoso and Aldo A. M. Lima; Bioinformatics, Lavouisier
- F.B. Nogueira and Marco A.F Clementino; *In vitro* validation of primers and sample
- testing, Marília S. Maia, Lavouisier F.B. Nogueira,; Data analysis, Jose Q.S. Filho;
- 381 Deiziane V.S. Costa, José K. Sousa, and Aldo A.M. Lima.
- Written review and editing, Marília S. Maia, Lavouisier F.B. Nogueira, and Aldo A.M.
- Lima; Supervision, Alexandre Havt and Aldo A.M. Lima; Project administration, Aldo
- 384 A.M. Lima; Resource acquisition, Aldo A.M. Lima.
- Funding: This research was funded by CNPq (http://www.cnpq.br), grant numbers
- 386 402607/2018-0 and 408549/2022-0 and FUNCAP (https://www.funcap.ce.gov.br/),
- grant number: OFÍCIO Nº 102/2021 DINOV.
- 388 Data Availability Statement: The data and reports relating to this study will be
- available via direct request via email to the corresponding author.
- 390 **Conflicts of Interest**: The authors declare that there are no financial or personal
- 391 conflicts of interest that may have influenced the work.

References

392


- 393 1. WHO. Media Center. WHO publishes list of bacteria for which new antibiotics are
- urgently needed. World Health Organization: 27 Fev., 2017.


- 395 2. FLEECE, ME. et al. Molecular diagnosis of antimicrobial resistance in Escherichia
- 396 *coli.* **Expert Rev Mol Diagn**, v.18, n. 3, p.207-217, 2018.
- 397 3. AMARAL, MVF et al. Prevalência de microorganismos multirresistentes em um
- 398 hospital universitário análise de uma série histórica. In: II Congresso Brasileiro de Medicina
- Hospitalar II CBMH. **Blucher Medical Proceedings**, v 1, n 5, p.70, 2014.
- 400 4. CARVALHO, MR. et al. Incidência de bactérias multirresistentes em uma unidade de
- 401 terapia intensiva. **Revista Interdisciplinar**, v.8, n.2, p. 75-85, 2015.
- 402 5. BOTELHO, J.; GROSSO, F.; PEIXE, L. Antibiotic resistance in *Pseudomonas*
- 403 aeruginosa Mechanisms, epidemiology and evolution, Drug Resistance Updates, v. 44,
- 404 p.26–47, 2019.
- 405 6. JURADO-MARTÍN, I.; SAINZ-MEJÍAS, M.; MCCLEAN, S. Pseudomonas
- 406 aeruginosa: An Audacious Pathogen with an Adaptable Arsenal of Virulence Factors. Int. J.
- 407 **Mol. Sci.** v.22, p.3128, 2021.
- 408 7. EUROPEAN CENTER FOR DISEASE PREVENTION AND CONTROL (ECDC),
- 409 Surveillance of antimicrobial resistance in Europe, Annual report of the European Antimicrobial
- 410 Resistance Surveillance Network (EARS-Net), 2016.
- 411 8. CAI, Y. et al. Prevalence of Healthcare- Associated Infections and Antimicrobial Use
- 412 Among Adult Inpatients in Singapore Acute-Care Hospitals: Results From the First National
- 413 Point Prevalence Survey. Clin Infect Dis. v.64, n. 2, p.S61–S67, 2017.
- 414 9. ROSSI, E. et al. *Pseudomonas aeruginosa* adaptation and evolution in patients with
- 415 cystic fibrosis. **Nat. Rev. Microbiol**. v.19, p.331–342, 2021.
- 416 10. ESCANDÓN-VARGAS K. et al. The epidemiology of carbapenemases in Latin
- 417 America and the Caribbean. Expert Rev Anti Infect Ther. 2017 Mar;15(3):277–297.
- 418 11. TENOVER, FC.; NICOLAU, DP.; Gill, CM. Carbapenemase-producing *Pseudomonas*
- 419 *aeruginosa* -an emerging challenge. **Emerg Microbes Infect.** v.11, n.1, p.811-814, 2022.
- 420 12. WALTERS MS. et al. Carbapenem- resistant Pseudomonas aeruginosa at US Emerging
- 421 infections program sites, 2015. Emerging Infect Dis. 2019 Jul;25(7):1281–1288.
- 422 13. LI, XZ.; PLÉSIAT, P.; NIKAIDO, H. The challenge of efflux-mediated antibiotic
- resistance in Gram-negative bacteria. **Clin Microbiol Rev.** v. 28, n. 2, p.337-418, 2015.
- 424 14. LV, L. et al. Emergence of a Plasmid-Encoded Resistance-NodulationDivision Efflux
- 425 Pump Conferring Resistance to Multiple Drugs, Including Tigecycline, in Klebsiella
- 426 *pneumoniae*. **mBio**, v.11, p.e02930-19, 2020.
- 427 15. NI, R. et al. The role of RND-type efux pumps in multidrug-resistant mutants of
- 428 *Klebsiella pneumoniae*. **Nature**, v. 10, p.10876, 2020.
- 429 16. CLSI, Clinical and Laboratory Standards Institute, M100, 30th ed., January, 2020.
- 430 17. BrCAST, Brazilian Committee on Antimicrobial Susceptibility Testing, March, 2020.
- 431 18. BrCAST, Brazilian Committee on Antimicrobial Susceptibility Testing, May, 2021.


- 432 19. NOGUEIRA et al. Molecular insights of β-lactams resistance in *Klebsiella pneumoniae*
- 433 isolates with focus on multidrug resistance and virulence from colonization samples. medRxiv,
- 434 2023.
- 435 20. URZEDO, JE. et al. High mortality by nosocomial infections caused by carbapenem-
- 436 resistant P. aeruginosa in a referral hospital in Brazil: facing the perfect storm. J Med
- **Microbiol.** v.69, n.12, p.1388-1397, 2020.
- 438 21. AGÊNCIA NACIONAL DE VIGILÂNCIA SANITÁRIA (ANVISA). REDE
- 439 NACIONAL DE MONITORAMENTO DA RESISTÊNCIA MICROBIANA EM SERVIÇOS
- 440 DE SAÚDE Boletim Segurança do Paciente e Qualidade em Serviços de Saúde nº 28 -
- 441 Avaliação Nacional dos indicadores de IRAS e RM, Brasília: ANVISA, 2021.
- 442 22. SADER HS, et al. Antimicrobial susceptibility of Gram-negative bacteria from
- intensive care unit and non-intensive care unit patients from United States hospitals (2018-
- 444 2020). **Diagn Microbiol Infect Dis.** v.102, n. 1, p.115557, 2022.
- 445 23. DUNPHY LJ et al. Multidimensional Clinical Surveillance of Pseudomonas aeruginosa
- 446 Reveals Complex Relationships between Isolate Source, Morphology, and Antimicrobial
- 447 Resistance. **mSphere**. v. 6, n. 4, p. e0039321, 2021.
- 448 24. NUNES, L.H.D.S. et al., Pseudomonas aeruginosa in tracheal aspirate: Colonization,
- infection, and recurrence. **Clin Respir J.** v.17, n.5, p.439-446, 2023.
- 450 25. BABICH, T. et al., Ceftazidime, Carbapenems, or Piperacillin-tazobactam as Single
- 451 Definitive Therapy for *Pseudomonas aeruginosa* Bloodstream Infection: A Multisite
- 452 Retrospective Study. **Clin Infect Dis.,** v.70, n.11, p.2270-2280, 2020.
- 453 26. FREIFELD, A.G. et al. Clinical practice guideline for the use of antimicrobial agents in
- neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America.
- 455 **Clin Infect Dis**, v.52, p.e56–e93, 2011.
- 456 27. SANTOS IC, Epidemiology and antibiotic resistance trends in clinical isolates of
- 457 Pseudomonas aeruginosa from Rio de janeiro Brazil: Importance of mutational mechanisms
- 458 over the years (1995-2015). **Infect Genet Evol.** v. 73, p. 411-415, 2019.
- 459 28. HAIDAR, G. et al. Ceftolozanetazobactam for the treatment of multidrug-resistant
- 460 Pseudomonas aeruginosa infections: clinical effectiveness and evolution of resistance. Clin
- **Infect Dis.** v. 65, p. 110–120, 2017.
- 462 29. MUNITA, JM. Et al. Multicenter evaluation of ceftolozane/tazobactam for serious
- infections caused by carbapenem-resistant *Pseudomonas aeruginosa*. Clin Infect Dis. v. 65, p.
- 464 158–161, 2017.
- 465 30. DRAWZ, SM.; PAPP-WALLACE, KM.; BONOMO, RA. New β-lactamase inhibitors:
- a therapeutic renaissance in an MDR world. **Antimicrob Agents Chemother**. v. 58, p.1835–
- 467 1846, 2014.


- 468 31. LÓPEZ-CALLEJA, AI. et al., Antimicrobial activity of ceftolozane-tazobactam against
- 469 multidrug-resistant and extensively drug-resistant *Pseudomonas aeruginosa* clinical isolates
- 470 from a Spanish hospital. **Rev Esp Quimioter.** v.32, n.1, p.68-72, 2019.
- 471 32. KARLOWSKY, JA. et al. In vitro activity of ceftazidime-avibactam against
- 472 Enterobacterales and Pseudomonas aeruginosa isolates collected in Latin America as part of the
- 473 ATLAS global surveillance program, 2017-2019. **Braz J Infect Dis.** v.25, n.6, p.101647, 2021.
- 474 33. HU, Y. et al. Prevalence, Risk Factors, and Molecular Epidemiology of Intestinal
- 475 Carbapenem-Resistant *Pseudomonas aeruginosa*. **Microbiol Spectr.** v.9, n.3, p.e0134421,
- 476 2021.
- 477 34. REYES, J. et al., Antibacterial Resistance Leadership Group and Multi-Drug Resistant
- 478 Organism Network Investigators. Global epidemiology and clinical outcomes of carbapenem-
- 479 resistant *Pseudomonas aeruginosa* and associated carbapenemases (POP): a prospective cohort
- 480 study. **Lancet Microbe.** v.4, n.3, p.e159-e170, 2023.
- 481 35. CASTANHEIRA, M.; SIMNER, P.; BRADFORD, P. Extended-spectrum b-lactamases:
- an update on their characteristics, epidemiology and detection. **JAC Antimicrob Resist**, v. 16,
- 483 n. 3, p.1-21, 2021.
- 484 36. EVANS, BA.; AMYES, SG. OXA β-lactamases. Clin Microbiol Rev. v.27, n.2, p.241-
- 485 63, 2014.
- 486 37. KAITANY, KC. et al. Structures of the class D carbapenemases OXA-23 and OXA-146:
- 487 mechanistic basis of activity against carbapenems, extended-spectrum cephalosporins and
- aztreonam. Antimicrob. **Agents Chemother**. v.57, p.4848–4855, 2013.
- 489 38. LYON, J.A. Imipenem/cilastatin: the first carbapenem antibiotic. Drug Intell. Clin.
- **Pharm.** v. 19, p.895–899, 1985.
- 491 39. DIAS, V.C. et al. Epidemiological characteristics and antimicrobial susceptibility
- 492 among carbapenem-resistant non-fermenting bacteria in Brazil. **J Infect Dev Ctries.** v.10, n.6,
- 493 p.544-53, 2016.
- 494 40. LIU, LL. et al. Dissemination of blaOXA-23 in *Acinetobacter* spp. in China: main roles
- of conjugative plasmid pAZJ221 and transposon Tn2009. **Antimicrob Agents Chemother**. v.
- 496 59, n.4, p.1998-2005, 2015.
- 497 41. ZONG, G. et al. The carbapenem resistance gene bla_{OXA-23} is disseminated by a
- 498 conjugative plasmid containing the novel transposon Tn6681 in Acinetobacter johnsonii M19.
- 499 Antimicrob Resist Infect Control. v. 9, n.1, p.182, 2020.
- 500 42. HAN, L et al. blaOXA-23-like and blaTEM rather than blaOXA-51-like contributed to a
- 501 high level of carbapenem resistance in Acinetobacter baumannii strains from a teaching hospital
- 502 in Xi'an, **China. Medicine** (**Baltimore**), v. 96, n. 48, p.e8965, 2017.
- FOR AGE AND SOLUTION S.; RAMAZANZADEH, R. Prevalence of bla_{Oxacillinase-23} and bla_{Oxacillinase-24/40}.
- 504 type Carbapenemases in Pseudomonas aeruginosa Species Isolated From Patients With

- Nosocomial and Non-nosocomial Infections in the West of Iran. Iran J Pathol. v. 13, n. 3,
- p.348-356, 2018.
- 507 44. LEE, YT. et al. First identification of blaOXA-51-like in non-baumannii Acinetobacter
- 508 spp. **J Chemother.** v.21, n.5, p.514-20, 2009.
- 509 45. NITZ, F. et al. Molecular Detection of Drug-Resistance Genes of *bla*_{OXA-23}-*bla*_{OXA-51} and
- 510 mcr-1 in Clinical Isolates of Pseudomonas aeruginosa. Microorganisms. v. 9, n.4, p. 786,
- 511 2021.
- 512 46. LORUSSO, AB. et al. Role of Efflux Pumps on Antimicrobial Resistance in
- 513 *Pseudomonas aeruginosa.* **Int J Mol Sci.** v.23, n.24, p.15779, 2022.
- 514 47. OLIVEIRA, W.K. et al. Resistome Analysis of Bloodstream Infection Bacterial
- Genomes Reveals a Specific Set of Proteins Involved in Antibiotic Resistance and Drug Efflux.
- **NAR Genom. Bioinforma**, v.2, p. lqaa055, 2020.










Percentage (%)



Percentage (%)